Esperion Therapeutics (ESPR) moves to remove its Nasdaq listing
Filing Impact
Filing Sentiment
Form Type
25-NSE
Rhea-AI Filing Summary
Esperion Therapeutics, Inc. is removing its common stock from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq certifies that it has complied with its rules and the applicable provisions of 17 CFR 240.12d2-2 to strike this class of securities from listing and/or withdraw its registration.
Positive
- None.
Negative
- None.
Key Figures
Commission File Number: 001-35986
Rule citation: 17 CFR 240.12d2-2(b)
Rule citation: 17 CFR 240.12d2-2(c)
3 metrics
Commission File Number
001-35986
File number for Esperion Therapeutics, Inc. under the Exchange Act
Rule citation
17 CFR 240.12d2-2(b)
Cited as the basis for the Exchange striking the class of securities
Rule citation
17 CFR 240.12d2-2(c)
Cited regarding issuer compliance for voluntary withdrawal from listing
Key Terms
Form 25, Section 12(b), 17 CFR 240.12d2-2, withdrawal of the class of securities
4 terms
Form 25 regulatory
"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.
Section 12(b) regulatory
"REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934"
Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.
17 CFR 240.12d2-2 regulatory
"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied"
A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.
withdrawal of the class of securities regulatory
"governing the voluntary withdrawal of the class of securities from listing"
FAQ
What action is Esperion Therapeutics (ESPR) taking in this Form 25 filing?
Esperion Therapeutics, Inc. is removing its common stock from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934, as reflected in this Form 25 notification.
Which securities of Esperion Therapeutics (ESPR) are affected by this delisting?
The filing covers Esperion Therapeutics’ common stock as the affected class of securities. Nasdaq indicates that this class is being struck from listing and/or withdrawn from registration pursuant to 17 CFR 240.12d2-2.
Which exchange is Esperion Therapeutics (ESPR) leaving according to this document?
Esperion Therapeutics’ common stock is being removed from listing on the Nasdaq Stock Market LLC. Nasdaq certifies that it has followed its own rules and 17 CFR 240.12d2-2 to effect this removal.
Under what regulatory authority is Esperion Therapeutics (ESPR) being delisted?
The delisting proceeds under Section 12(b) of the Securities Exchange Act of 1934 and 17 CFR 240.12d2-2. The document references both Rule 12d2-2(b) and Rule 12d2-2(c) as the governing provisions.
What is the Commission File Number for Esperion Therapeutics (ESPR) in this Form 25?
The Commission File Number associated with Esperion Therapeutics, Inc. in this Form 25 is 001-35986. This number uniquely identifies the issuer’s registration under the Securities Exchange Act of 1934.